Monoamine depletion studies: Implications for antidepressant discontinuation syndrome

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 4, 2006, Pages 22-26

  Delgado, Pedro L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; FENCLONINE; FLUOXETINE; FLUVOXAMINE; METHYSERGIDE; METIROSINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN; TYROSINE 3 MONOOXYGENASE;

ANOREXIA; ANXIETY; ASTHENIA; ATAXIA; BEHAVIOR THERAPY; CATECHOLAMINE DEPLETION; CENTRAL NERVOUS SYSTEM; CHILL; CLINICAL FEATURE; COGNITIVE THERAPY; DEPRESSION; DIAPHORESIS; DIARRHEA; DISCONTINUATION SYNDROME; DISEASE COURSE; DIZZINESS; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG WITHDRAWAL; EMOTIONALITY; FATIGUE; GAIT DISORDER; HEADACHE; HUMAN; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LETHARGY; MONOAMINE METABOLISM; MOOD DISORDER; MYALGIA; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEURALGIA; NEUROBIOLOGY; NONHUMAN; PARESTHESIA; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SHOCK; SIDE EFFECT; SLEEP DEPRIVATION; SUICIDAL IDEATION; TREMOR; VERTIGO; VISUAL DISORDER; VIVID DREAM; VOMITING; WITHDRAWAL SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; DOPAMINE; HUMANS; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SYNAPSES; TRYPTOPHAN;

EID: 33646801936     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry 1997;58(suppl 7):5-10
2. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989;8:52-62
3. Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 1996;3:75-83
4. Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 1997;58(suppl 7):23-27
5. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000;61:7-11
6. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999;46:212-220
7. Sjoerdsma A, Engelman K, Spector S, et al. Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 1965;286:1092-1094
8. Young SN, Smith SE, Pihl RO, et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacol (Berl) 1985;87:173-177
9. Delgado PL, Moreno FA, Onate L, et al. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002;5:63-66
10. Curzon G. Relationships between plasma, CSF and brain tryptophan. J Neural Transm Suppl 1979;15:81-92
11. Curzon G. Influence of plasma tryptophan on brain 5HT synthesis and serotonergic activity. Adv Exp Med Biol 1981;133:207-219
12. Fernstrom JD. Effects on the diet on brain neurotransmitters. Metab 1977;26:207-223
13. Moja EA, Cipolla P, Castoldi D, et al. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci 1989;44:971-976
14. Young SN, Ervin FR, Pihl RO, et al. Biochemical aspects of tryptophan depletion in primates. Psychopharmacol (Berl) 1989;98:508-511
15. Benkelfat C, Ellenbogen MA, Dean P, et al. Mood-lowering effect of tryptophan depletion: enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994;51:687-697
16. Delgado PL, Charney DS, Price LH, et al. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci 1989;45:2323-2332
17. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A 1997;94:5308-5313
18. Perez-Cruet J, Chase TN, Murphy DL. Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans. Nature 1974;248:693-695
19. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-919
20. Young VR, Hussein MA, Murray E, et al. Tryptophan intake, spacing of meals, and diurnal fluctuations of plasma tryptophan in men. Am J Clin Nutr 1969;22:1563-1567
21. Young VR, Hussein MA, Murray E, et al. Plasma tryptophan response curve and its relation to tryptophan requirements in young adult men. J Nutr 1971;101:45-59
22. Moreno FA, McGavin C, Malan TP, et al. Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling technique. Int J Neuropsychopharmacol 2000;3:277-283
23. Leyton M, Young SN, Blier P, et al. The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacol 1997;16:294-297
24. Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000;48:327-329
25. Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-330
26. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874
27. Miller HL, Delgado PL, Salomon RM, et al. Effects of α-methyl-para- tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacol 1996;14:151-157
28. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
29. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396
30. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128
31. Moore P, Gillin C, Bhatti T, et al. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 1998;55:534-539
32. O'Reardor JP, Chopra MP, Bergan A, et al. Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants. Biol Psychiatry 2004;55:957-959
33. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Am J Psychiatry 1997;154:1153-1155
34. Neumeister A, Praschak-Rieder N, Besselmann B, et al. Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. Arch Gen Psychiatry 1997;54:133-138
35. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol Med 1998;28:257-264
36. Ashley DV, Curzon G. Effects of long-term low dietary tryptophan intake on determinants of 5-hydroxytryptamine metabolism in the brains of young rats. J Neurochem 1981;37:1385-1393
37. Vergnes M, Kempf E. Tryptophan deprivation: effects on mouse-killing and reactivity in the rat. Pharmacol Biochem Behav 1981;14(suppl 1):19-23
38. Walters JK, Davis M, Sheard MH. Tryptophan-free diet: effects on the acoustic startle reflex in rats. Psychopharmacol (Berl) 1979;62:103-109
39. Carpenter LL, Anderson GM, Pelton GH, et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacol 1998;19:26-35
40. Williams WA, Shoaf SE, Hommer D, et al. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J Neurochem 1999;72:1641-1647
41. Shansis FM, Busnello JV, Quevedo J, et al. Behavioural effects of acute tryptophan depletion in healthy male volunteers. J Psychopharmacol 2000;14:157-163
42. Moore P, Landolt HP, Seifritz E, et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacol 2000;23:601-622
43. Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:309-317
44. Huwig-Poppe C, Voderholzer U, Backhaus J, et al. The tryptophan depletion test: impact on sleep in healthy subjects and patients with obsessive-compulsive disorder. Adv Exp Med Biol 1999;467:35-42
45. Smeraldi E, Diaferia G, Erzegovesi S, et al. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 1996;40:398-402
46. 2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry 2000;176:182-188
47. Moreno FA, Rowe DC, Kaiser B, et al. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry 2002;7:213-216
48. Engelman K, Horwitz D, Jequier E, et al. Biochemical and pharmacologic effects of α-methyltyrosine in man. J Clin Invest 1968;47:577-594
49. Bunney WE Jr, Brodie HK, Murphy DL, et al. Studies of alpha-methylpara-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 1971;127:872-881
50. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003;64(suppl 13):26-29
51. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60
52. Delgado PL. The role of epinephrine in depression and anxiety. In: Kasper S, den Boer JA, Sitsen JMA, eds. Handbook of Depression and Anxiety, Second Edition. New York, NY: Marcel Dekker; 2003
53. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006;67(suppl 4):3-7
54. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255-261
55. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289
56. Pato MT, Murphy DL, DeVane C. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation [letter]. J Clin Psychopharmacol 1991;11:224-225
57. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
58. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154:1760-1762
59. Rose WC, Lambert GF, Coon MJ. The amino acid requirements of man, VII: general procedures: the tryptophan requirement. J Biol Chem 1954;211:815-827